Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Neuropharmacology. 2009 Jul 9;58(1):88–101. doi: 10.1016/j.neuropharm.2009.06.040

Table 6.

This table summarize results from the mPFC acquisition treatment (session 5) analyzed by gcRMA

Gene Title Fold
Change
latent transforming growth factor beta binding protein 2 3.2
carbonic anhydrase 3 2
Glutamine synthetase (glutamate-ammonia ligase) 2.3
ESTs, Highly similar to stomatin-like protein 2 [Mus musculus] [M.musculus] −2.1
ESTs, Weakly similar to FMOD_RAT Fibromodulin precursor (FM) [R.norvegicus] −2
ESTs 2.9
ESTs 2.6
ESTs −2.9
ESTs −2.2
ESTs −2.8
synaptic vesicle glycoprotein 2 b 2.8
ESTs 2.1
ESTs −3.8
ESTs, Weakly similar to AJ18 protein [Rattus norvegicus] [R.norvegicus] −2.3
ESTs 3.6
ESTs 2.2
ESTs, Weakly similar to T03096 CDO protein - rat [R.norvegicus] −2.9
ESTs 2.5
ESTs, Highly similar to Notch gene homolog 2, (Drosophila) [Rattus norvegicus]
[R.norvegicus]
−2.1
ESTs −2.4
ESTs −3.3
ESTs 2.9
ESTs, Highly similar to; protein transport protein SEC61 beta subunit [Homo sapiens] −2.4
ESTs, Highly similar to RETB_RAT Plasma retinol-binding protein precursor (PRBP) (RBP) −2.1
myelin-associated oligodendrocytic basic protein 2.1
N-ethylmaleimide sensitive factor 2.3
growth differentiation factor 8 −2.1
solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 2.6
cadherin 22 2.5
Myelin basic protein 2.8